Concord Biotech Share Price
₹2,129.35 +4.15 (0.2%)
21 Dec, 2024 18:40
Start SIP in
CONCORDBIO
Performance
- Low
- ₹2,096
- High
- ₹2,163
- 52 Week Low
- ₹1,322
- 52 Week High
- ₹2,664
- Open Price₹2,150
- Previous Close₹2,125
- Volume55,257
Investment Returns
- Over 1 Month + 12.02%
- Over 3 Month -18.14%
- Over 6 Month + 35.47%
- Over 1 Year + 57.8%
Smart Investing Starts Here Start SIP with Concord Biotech for Steady Growth!
Concord Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 67.9
- PEG Ratio
- 8.8
- Market Cap Cr
- 22,277
- P/B Ratio
- 14.6
- Average True Range
- 79.32
- EPS
- 31.35
- Dividend Yield
- 0.4
- MACD Signal
- 50.8
- RSI
- 55.06
- MFI
- 53.69
Concord Biotech Financials
Concord Biotech Technicals
EMA & SMA
-
- Bullish Moving Average 16
-
- Bearish Moving Average 0
- 20 Day
- ₹2,098.28
- 50 Day
- ₹2,019.18
- 100 Day
- ₹1,917.40
- 200 Day
- ₹1,751.23
Resistance and Support
- R3 2,229.75
- R2 2,196.35
- R1 2,162.85
- S1 2,095.95
- S2 2,062.55
- S3 2,029.05
Concord Biotech Corporate Actions - Bonus, Splits, Dividends
Concord Biotech F&O
About Concord Biotech
Concord Biotech Ltd. is leading biotechnology company in India, specializing in development & manufacturing of fermentation based biopharmaceuticals. Established in 2000, company has grown to become significant player in global biotech industry, with strong focus on immunosuppressants, oncology, & nephrology products. Concord Biotech's state of the art manufacturing facilities are designed to meet international quality standards, enabling company to supply its products to over 70 countries worldwide. company's dedication to innovation, research, & development has made it trusted partner in global healthcare industry.
diversified clientele: 200 clients in more than 70 countries use company's API & formulation solutions. long-term supply agreements with these clients accounted for 14.06%, 12.45%, & 12.56% of their revenues in FY21, FY22, & FY23.
R&D: Concord maintains specialized R&D facilities for formulations & APIs in Dholka & Valthera. Both have Indian DSIR's approval. Their R&D units employed 148 people as of March 31, 2022, making up 11.99% of their total number of permanent employees.
Domestic Presence: They sell range of 27 products in India, including immunosuppressants, nephrology medications, & anti-infective medications used in critical care. In India, they are present in 20 states & 5 union territories.
View More- NSE Symbol
- CONCORDBIO
- BSE Symbol
- 543960
- Chairman & Managing Director
- Mr. Sudhir Vaid
- ISIN
- INE338H01029
Similar Stocks to Concord Biotech
Concord Biotech FAQs
Concord Biotech share price is ₹2,129 As on 21 December, 2024 | 18:26
The Market Cap of Concord Biotech is ₹22276.5 Cr As on 21 December, 2024 | 18:26
The P/E ratio of Concord Biotech is 67.9 As on 21 December, 2024 | 18:26
The PB ratio of Concord Biotech is 14.6 As on 21 December, 2024 | 18:26
Consider company's product pipeline & growth prospects in biotech industry before investing.
Key metrics include revenue from key therapeutic areas, R&D investment, & profit margins.
Open Demat account with 5 Paisa Capital & post doing KYC & active account search for Concord Biotech share, you can then put order as you prefer.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.